Literature DB >> 22072802

PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.

Sauveur-Michel Maira1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22072802     DOI： 10.1158/1535-7163.MCT-11-0792

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN： 1535-7163            Impact factor:   6.261


× No keyword cloud information.
  10 in total

1.  PIK3CA mutations contribute to fulvestrant resistance in ER-positive breast cancer.

Authors:  Doudou Huang; Lin Tang; Fang Yang; Juan Jin; Xiaoxiang Guan
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

2.  Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Authors:  Valerie M Jansen; Neil E Bhola; Joshua A Bauer; Luigi Formisano; Kyung-Min Lee; Katherine E Hutchinson; Agnieszka K Witkiewicz; Preston D Moore; Mónica Valéria Estrada; Violeta Sánchez; Paula G Ericsson; Melinda E Sanders; Paula R Pohlmann; Michael J Pishvaian; David A Riddle; Teresa C Dugger; Wenyi Wei; Erik S Knudsen; Carlos L Arteaga
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

3.  CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.

Authors:  Sadhna R Vora; Dejan Juric; Nayoon Kim; Mari Mino-Kenudson; Tiffany Huynh; Carlotta Costa; Elizabeth L Lockerman; Sarah F Pollack; Manway Liu; Xiaoyan Li; Joseph Lehar; Marion Wiesmann; Markus Wartmann; Yan Chen; Z Alexander Cao; Maria Pinzon-Ortiz; Sunkyu Kim; Robert Schlegel; Alan Huang; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2014-07-04       Impact factor: 31.743

4.  Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.

Authors:  Davide Bommarito; Allison Martin; Edouard Forcade; Maria-Dorothea Nastke; Jerome Ritz; Roberto Bellucci
Journal:  Cancer Immunol Immunother       Date:  2016-02-16       Impact factor: 6.968

5.  Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.

Authors:  Rafaela Andrade-Vieira; Donna Goguen; Heidi A Bentley; Chris V Bowen; Paola A Marignani
Journal:  Oncotarget       Date:  2014-12-30

6.  Novel chloroquinoline derivatives incorporating biologically active benzenesulfonamide moiety: synthesis, cytotoxic activity and molecular docking.

Authors:  Mostafa M Ghorab; Mansour S Alsaid; Mohammed S Al-Dosari; Yassin M Nissan; Abdullah A Al-Mishari
Journal:  Chem Cent J       Date:  2016-04-05       Impact factor: 4.215

7.  Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.

Authors:  Hyun-Jung Kim; Soo Yoon Lee; Chan Young Kim; Yun Hwan Kim; Woong Ju; Seung Cheol Kim
Journal:  Oncotarget       Date:  2017-01-24

8.  Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.

Authors:  Chengying Xie; Xiangling Chen; Mingyue Zheng; Xiaohong Liu; Hongbin Wang; Liguang Lou
Journal:  Oncotarget       Date:  2017-11-14

9.  Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.

Authors:  Amos H P Loh; Rachel C Brennan; Walter H Lang; Robert J Hickey; Linda H Malkas; John A Sandoval
Journal:  Front Oncol       Date:  2013-04-23       Impact factor: 6.244

Review 10.  Evaluation of MicroRNAs Regulating Anoikis Pathways and Its Therapeutic Potential.

Authors:  Sharan Malagobadan; Noor Hasima Nagoor
Journal:  Biomed Res Int       Date:  2015-10-26       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.